Aquestive Therapeutics (AQST) Total Non-Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $169.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 5.08% year-over-year to $169.1 million; the TTM figure through Mar 2026 stood at $169.1 million (up 5.08% YoY), while the FY2025 annual figure was $186.8 million, up 17.36% from the prior year.
• Total Non-Current Liabilities was $169.1 million for Q1 2026 at Aquestive Therapeutics, down from $186.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $186.8 million in Q4 2025 to a low of $147.8 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $162.1 million across 5 years, with a median of $161.6 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 32.02% in 2022, then dropped 6.74% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $173.6 million in 2022, then dropped by 6.74% to $161.9 million in 2023, then dropped by 1.67% to $159.2 million in 2024, then grew by 17.36% to $186.8 million in 2025, then dropped by 9.47% to $169.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $169.1 million (Q1 2026), $186.8 million (Q4 2025), and $165.6 million (Q3 2025), per Business Quant data.